|
16 Oct 2021 |
GV20 Oncotherapy Completes Series B Financing to Advance Pipeline into the Clinic and Expand Immuno-Oncology Drug Discovery Platform
|
|
16 Oct 2021 |
Lundbeck receives exclusive rights to APB-A1, an innovative phase I-ready bio-therapeutic for the treatment of neuroimmune diseases from AprilBio
|
|
16 Oct 2021 |
FDA Approves Genentech’s Tecentriq as Adjuvant Treatment for Certain People With Early Non-Small Cell Lung Cancer
|
|
15 Oct 2021 |
Akeso is Rapidly Advancing The Phase II Clinical Trial of IL-4R Monoclonal Antibody (AK120) for the Treatment of Atopic Dermatitis and Asthma
|
|
15 Oct 2021 |
TG Therapeutics Announces Data for Ublituximab in Multiple Sclerosis Presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
|
|
15 Oct 2021 |
Imfinzi plus tremelimumab significantly improved overall survival in HIMALAYA Phase III trial in 1st-line unresectable liver cancer
|
|
14 Oct 2021 |
Roche’s Gazyvaro shorter 90-minute infusion time approved in Europe for people with previously treated or untreated follicular lymphoma
|
|
14 Oct 2021 |
Viridian Therapeutics Submits Investigational New Drug Application for VRDN-001, an IGF-1R antibody for the treatment of Thyroid Eye Disease, to the U.S. Food and Drug Administration
|
|
14 Oct 2021 |
TFF Pharmaceuticals and Augmenta Bioworks Publish Positive In Vivo Data Showing Dry Powder Formulation of COVID-19 Antibody, AUG-3387, Neutralizes SARS-CoV-2 Infection and Reduces Viral Load
|
|
14 Oct 2021 |
Tentarix Biotherapeutics Emerges with $50 Million Series A
|
|
14 Oct 2021 |
Tizona Initiates Phase 1b Expansion Study of TTX-080 in Advanced Refractory or Resistant Malignancies
|
|
14 Oct 2021 |
FDA Accepts REGEN-COV® (casirivimab and imdevimab) for Priority Review for Treatment and Prophylaxis of COVID-19
|
|
14 Oct 2021 |
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Bevacizumab, as Treatment for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS ≥1)
|
|
13 Oct 2021 |
Agenus to Receive $20M Milestone Payment from Bristol Myers Squibb with Dosing of First Patient with its TIGIT Bispecific Antibody
|
|
13 Oct 2021 |
INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency and Demonstrates the Potential to Achieve Normal Alpha-1 Antitrypsin Levels with Monthly Dosing
|
|
12 Oct 2021 |
TRACON Pharmaceuticals and Eucure Biopharma, a Subsidiary of Biocytogen, Announce Partnership for Development of Clinical Stage CTLA-4 Antibody YH001
|
|
11 Oct 2021 |
CatalYm Presents Updated Tolerability and Preliminary Pharmacodynamics Data from GDF-15 Targeting First-in-Human Clinical Trial in Plenary Session at AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics
|
|
11 Oct 2021 |
AZD7442 reduced risk of developing severe COVID-19 or death in TACKLE Phase III outpatient treatment trial
|
|
09 Oct 2021 |
Acumen Announces First Patient Dosed in a Phase 1 Clinical Trial of ACU193, a Monoclonal Antibody that Selectively Targets Toxic Aβ Oligomers for the Treatment of Early Alzheimer’s Disease
|
|
09 Oct 2021 |
Jounce Therapeutics Progresses INNATE Study of JTX-8064 (LILRB2/ILT4 Inhibitor) Monotherapy and Pimivalimab (PD-1 Inhibitor) Combination Therapy in Patients with Advanced Solid Tumors
|
|
09 Oct 2021 |
Amunix Presents Preclinical Data on Its XPAT T Cell Engager Platform at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics
|
|
09 Oct 2021 |
Mersana Therapeutics Announces Target and Presents New Preclinical Data for XMT-2056, First Immunosynthen STING-Agonist ADC, at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
|
|
09 Oct 2021 |
Inhalon Doses First Patient in Phase 1 Study of Inhaled IN-006 to Treat COVID-19
|
|
09 Oct 2021 |
Kineta Presents Preclinical Data on Its New CD27 Program at the AACR Conference on Tumor Immunology and Immunotherapy
|
|
09 Oct 2021 |
Brii Bio Initiates Submission of Emergency Use Authorization Filing to U.S. FDA for BRII-196/BRII-198, its Monoclonal Antibody Combination Therapy for Non-Hospitalized COVID-19 Patients at High Risk of Clinical Progression to Severe Disease
|
